An innovative diagnostic device manufacturer Nano-X Imaging Ltd. (NNOX), has written a letter to the US Food and Drug Administration (FDA). This has become a driver of growth in quotations. NNOX’s share price rose 9 % at the auction on June 17 to $30.5.
Nano-X Imaging Ltd. (NNOX) closed the previous trading day at $27.98. Shares were traded at a volume of 8.05 million, much higher than the average volume over the last three months of 2.53 million. It fluctuated between $29.63 and $33.35 during the trading session. The company had an earnings per share ratio of -1.12. NNOX’s stock has gained 6.42% of its value in the previous five sessions and moved 25.67% over the past one month but has lost -33.20% on a year-to-date basis. The stock’s 50-day moving average of $29.18 is below the 200-day moving average of $41.42. Moreover, the stock has an RSI of 58.02 at present.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As soon as it was revealed, the FDA had received a letter asking for permission to sell Nanox.ARC 3D tomography, the stock shot up. X-ray imaging with multi-source and multi-sensors is an innovative system combining multiple sources and sensors into one compact package. According to the company itself, the cost of the Nano-X tomograph will be lower than that of existing counterparts with characteristics sufficient for high-quality diagnostics.
This company has already received medical approval for the development of Nano-X. On the other hand, certain local laws require prior notification to the regulator before a medical device is sold directly to the public. This is necessary to check the conformity of the serial production with the previously approved demo. After the regulator evaluates the Nano-X and finds no significant differences in the characteristics, it will become available for sale.
For Nano-X Imaging Ltd. (NNOX) investors, announcing a possible early sales start was welcome news. The Nano-X team of specialists has developed a great MRI scanner that can easily be commercialized. A subscription to the scanner operation is a good solution for hospitals, which cannot afford expensive and analogous machines with more extreme specifications.
